"NR7859" Dotaz Zobrazit nápovědu
Závěrečná zpráva o řešení grantu Interní grantové agentury MZ ČR
Přeruš. str. : tab., il. ; 30 cm
The clinical significance of antibodies against HLA antigens (alloantibodies) in patients after kidney transplantation and its relation to chronic rejection is not still completely elucidated. The aim of this study is to investigate the correlation between antibodies to HLA antigens after transplantation and the morphological and clinical symptoms of chronic rejection. Alloantibodies will be analyzed according to their HLA (or non-HLA) specificity, immunoglobulin class and dynamics of development.
Klinický význam vzniku protilátek proti HLA antigenům (aloprotilátek) u pacientů po transplantaci ledviny a jejich vztah k chronické rejekci není zatím dostatečně vyjasněn. V navrhovaném projektu si klademe za cíl studovat korelaci mezi vznikem protilátek proti HLA antigenům po transplantaci a morfologickými a klinickými příznaky chronické rejekce. Protilátky budou analyzovány podle jejich specificity proti HLA antigenům, dynamiky vzniku a imunoglobulinové třídy.
- MeSH
- chronická nemoc MeSH
- ELISA MeSH
- histocytochemie MeSH
- HLA antigeny imunologie MeSH
- průtoková cytometrie MeSH
- rejekce štěpu komplikace MeSH
- transplantace ledvin škodlivé účinky MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- alergologie a imunologie
- nefrologie
- transplantologie
- NLK Publikační typ
- závěrečné zprávy o řešení grantu IGA MZ ČR
The aim of our retrospective study was to evaluate the clinical significance of measurement of the soluble CD30 (sCD30) molecule for the prediction of antibody-mediated (humoral) rejection (HR). Sixty-two kidney transplant recipients (thirty-one C4d-positive and thirty-one C4d-negative patients) were included into the study. Soluble CD30 levels were evaluated before transplantation and during periods of graft function deterioration. The median concentrations of the sCD30 molecule were identical in C4d-positive and C4d-negative patients before and after transplantation (65.5 vs. 65.0 and 28.2 vs. 36.0 U/ml, respectively). C4d+ patients who developed DSA de novo had a tendency to have higher sCD30 levels before transplantation (80.7+/-53.6 U/ml, n=8) compared with C4d-negative patients (65.0+/-33.4 U/ml, n=15). Soluble CD30 levels were evaluated as positive and negative (>or=100 U/ml and <100 U/ml respectively) and the sensitivity, specificity and accuracy of sCD30 estimation with regard to finding C4d deposits in peritubular capillaries were determined. The sensitivity of sCD30+ testing was generally below 40%, while the specificity of the test, i.e. the likelihood that if sCD30 testing is negative, C4d deposits would be absent, was 82%. C4d+ patients who developed DSA de novo were evaluated separately; the specificity of sCD30 testing for the incidence of HR in this cohort was 86%. CONCLUSION: We could not confirm in our study that high sCD30 levels (>or=100 U/ml) might be predictive for the incidence of HR. Negative sCD30 values might be however helpful for identifying patients with a low risk for development of DSA and antibody-mediated rejection.
- MeSH
- antigen Ki-1 analýza MeSH
- dospělí MeSH
- financování organizované MeSH
- homologní transplantace MeSH
- komplement C4b analýza MeSH
- lidé středního věku MeSH
- lidé MeSH
- peptidové fragmenty analýza MeSH
- protilátky imunologie MeSH
- rejekce štěpu imunologie MeSH
- senioři MeSH
- transplantace ledvin imunologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
